Bajajfinsv FY25 Annual Earnings Summary
4 quarters covered · ₹1,33,820 Cr revenue · ₹17,557 Cr PAT · 28.0% average EBITDA margin.
Quarter-by-quarter progression
Management promises made during the year
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q1 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q1 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q1 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q2 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q2 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q3 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q3 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q3 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q4 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q4 FY25Risks flagged during the year
BFL's loan losses and provisions were elevated in Q1 due to muted collection efficiencies and increase in stage 2 assets by INR 864 crore.
Q2 FY25 · highAllianz has informed Bajaj of its decision to exit the joint venture; management provided no further details, creating uncertainty around future ownership and operations.
Q3 FY25 · highNew surrender value guidelines have impacted product mix and distribution, with agency channel taking longer to adjust.
Q3 FY25 · highAllianz's intention to exit the JV is at preliminary stage; no details provided, creating strategic uncertainty.
Q1 FY25 · mediumNew IRDA surrender value norms may temporarily slow margin expansion; management was evasive on quantifying the impact.
Q1 FY25 · mediumThough termed one-offs, large property and liability claims caused combined ratio deterioration; similar claims could arise in future.
Q1 FY25 · mediumInsurance partners of Vidal may withdraw business due to conflict of interest with Bajaj Finserv's insurance arms.
Q2 FY25 · mediumVNB margins fell 3.8pp YoY to 9.2% due to higher ULIP sales; new surrender value norms may further pressure margins.
Q2 FY25 · mediumNo TP price hike for three years has led to underwriting losses; management has reduced exposure, capping motor growth.
Q2 FY25 · mediumMedical inflation and hospital fraud are squeezing margins; management is cautious on growth in this segment.
Q3 FY25 · mediumIRDAI capping senior citizen premium hikes and EOM limits may pressure margins, though Bajaj is well-positioned.
Q4 FY25 · mediumThe 1/n regulation for long-term products distorted GWP and combined ratio comparability, and further regulatory shifts could affect reported metrics.
What changed through the year
Q1 FY25 · BAGIC expects combined ratio to normalize in subsequent quarters
Management indicated that large commercial claims in Q1 are one-offs and not expected to recur, with combined ratio likely improving.
Q1 FY25 · BALIC margins may see a pause in expansion this year due to surrender regulations
New surrender value norms could temporarily impact margin expansion, but medium-term expansion expected through product filings and cost optimization.
Q1 FY25 · BFL expects collection efficiency to improve in H2
Steps taken to strengthen collections and slow rural B2C business should yield results in the second half of FY25.
Q1 FY25 · Bajaj Finserv Health to provide long-term plan in 6-9 months
Post-Vidal acquisition, management will outline a complete long-range plan including breakeven visibility within 6-9 months.
Q2 FY25 · BALIC VNB margin improvement in H2
Management expects VNB margins to improve in H2 as product mix rebalances away from ULIPs and commission deferrals take effect.
Q2 FY25 · Bajaj Finserv Direct breakeven in 1-2 quarters
The marketplace business expects to break even on a cash basis within the next couple of quarters.
Q2 FY25 · Capital deployment of ₹500-600 crore in health & AMC by Mar'26
BFL plans to invest ₹500-600 crore in health tech and asset management over the next 18 months.
Q2 FY25 · BAGIC core growth to remain above market
Management expects core premium growth to continue outpacing the industry, driven by disciplined underwriting.
Q3 FY25 · BALIC VNB growth to outpace top-line growth
Management expects VNB to grow faster than top-line due to product structure changes and focus on profitability.
Q3 FY25 · BAGIC to maintain combined ratio better than market
Continued focus on profitable growth with combined ratio superior to industry average.
Q3 FY25 · BFL to reduce loan losses next year
Management committed to bringing down loan losses in the coming year.
Q4 FY25 · BALIC VNB margin trajectory to steepen
Management expects VNB margin expansion to accelerate, with benefits from cost actions and product mix fully playing out by FY27, but visible from H2 FY26.
Q4 FY25 · BALIC top-line growth to pick up from H2 FY26
After a muted H1 due to high base and agency channel reset, growth is expected to recover in the second half of FY26.
Q4 FY25 · BAGIC to continue calibrated growth with underwriting focus
Management aims to maintain profitable growth, prioritizing underwriting performance over market share in tender-driven businesses.
Q4 FY25 · Platform businesses to scale transactions
Bajaj Finserv Health and Bajaj Markets are expected to increase transaction volumes and achieve greater scale, with health targeting international expansion.